Smart Contact Lens IOP Monitoring: 2026 Patent Landscape
Smart Contact Lens IOP Monitoring: 2026 Landscape
Smart contact lenses combining MEMS sensing, wireless telemetry, and AI analytics are addressing the critical gap in continuous glaucoma management. Single in-office measurements miss nocturnal IOP peaks that drive disease progression in a condition projected to affect 60–112 million people globally by 2040.
Continuous IOP Monitoring: From Single-Point Tonometry to Wearable Sensing
The core clinical problem is well-established: Goldmann applanation tonometry delivers only a single-point measurement during office hours, while IOP follows a circadian rhythm with peaks frequently occurring between 11 PM and 5 AM. Most glaucoma patients have their highest IOP measurements outside clinic hours, and these undetected peaks may explain why patients progress despite treatment.
Within this dataset, the dominant platform is the soft contact lens embedded with pressure-sensitive transducers and wireless communication circuits. Five technical sub-domains have been identified: MEMS-based strain gauge and capacitive sensors, microfluidic and optical indicator systems, implantable telemetric sensors, AI-augmented closed-loop theranostic systems, and non-contact peripheral wearables including smart glasses and infrared tonometers.
The innovation timeline spans three phases from 2001 to 2026. The foundational phase (2001–2013) established core architectures via EPFL and Leuenberger. The development and clinical validation phase (2014–2021) saw commercialization of the Sensimed Triggerfish, which gained FDA approval for 24-hour IOP-related pattern monitoring. The current integration and AI phase (2022–2026) reflects a shift toward multi-modal, AI-integrated, closed-loop systems.
In this dataset, Kingston Health Sciences Centre is the most prolific assignee by retrieved filing count with approximately 7 filings across US, CA, and WO jurisdictions. Indian academic institutions collectively account for approximately 18 retrieved filings distributed across 15+ assignees, representing the highest single-jurisdiction volume in retrieved records, though nearly all are pending and at concept-patent stage.
Technology Cluster Distribution and Filing Trends
Analysis of retrieved records reveals four primary technology clusters with distinct maturity profiles, alongside a surge of filings from 2022 onward driven by AI integration and closed-loop theranostic architectures.
Patent Filings by Technology Cluster (Dataset Snapshot)
MEMS strain gauge and capacitive sensor lenses represent the most commercially mature cluster in this dataset, anchored by Sensimed SA’s Triggerfish CLS and active filings from Glakolens and multiple Indian institutions.
↗ Click bars to exploreRetrieved Filings by Innovation Phase (Dataset Snapshot)
The integration and AI phase (2022–2026) shows the strongest filing density in this dataset, with 12 Indian-jurisdiction filings alone dated 2024–2026 and several US/WO filings from Kingston Health Sciences Centre and SmartLens Inc. dated 2025.
↗ Click bars to exploreKey Clinical and Deployment Contexts for Smart IOP Monitoring
Retrieved patents and literature span four primary application domains, from hospital-grade glaucoma management to low-resource point-of-care screening, each with distinct technical requirements and regulatory pathways.
Continuous Glaucoma Monitoring
This is the primary application domain across the dataset. Clinical literature confirms that glaucoma progressors show significantly higher nocturnal IOP peaks than stable patients (P = 0.009 in a 40-patient study). The Sensimed Triggerfish CLS gained FDA approval for 24-hour IOP-related pattern monitoring, and Kingston Health Sciences Centre’s microfluidic lens portfolio targets the same continuous profiling need.
Glaucoma ManagementMulti-Biomarker Ocular Diagnostics
Several retrieved filings extend beyond IOP to simultaneous monitoring of tear glucose, potassium ion levels, ocular surface temperature, and inflammation markers. The smart contact lens for monitoring glucose and eye pressure (Dr. K. Sivakumar, IN, 2021) and the contact lens system monitoring pressure, moisture, and potassium levels (Alqattan, US, 2022) illustrate this multi-modal trend targeting the glaucoma-diabetes overlap.
Multi-Analyte SensingRemote Telemedicine IOP Care
A 2021 feasibility study documented 37 patients with implanted telemetric IOP sensors (Eyemate; Implandata GmbH) successfully obtaining home IOP measurements during COVID-19 lockdown. The Advanced Ophthalmics LLC Ocular System and Method (US, 2019) explicitly targets remote IOP telemetry for glaucoma drainage management. Cloud connectivity is described as a near-universal feature in 2024–2026 filings in this dataset.
Remote MonitoringLow-Resource IOP Screening
The Vidyavardhaka College of Engineering (IN, 2025) portable device uses corneal surface temperature measured via infrared sensors as a low-cost proxy for IOP, requiring no anesthesia and targeting rural and underserved clinical settings. The Medgenisis portable tool from Koneru Lakshmaiah Education Foundation (IN, 2025) adds cloud-based remote ophthalmologist access to a portable IOP screening device for similarly resource-limited deployments.
Point-of-Care ScreeningKey Patent Assignees in Smart IOP Monitoring (Retrieved Records)
In this dataset, Kingston Health Sciences Centre is the most prolific single assignee with approximately 7 retrieved filings across US, CA, and WO jurisdictions, all deriving from a 2016 priority date. Sensimed SA accounts for approximately 4 retrieved filings and holds the only FDA-cleared continuous IOP monitoring contact lens product represented in retrieved records.
Top Assignees by Retrieved Filing Count (Dataset Snapshot)
↗ Click bars to exploreKingston Health Sciences Centre
The most prolific single assignee in this dataset with approximately 7 retrieved filings across US, CA, and WO jurisdictions — all deriving from a 2016 priority date and continuously extended through 2025. Patents cover a flexible contact lens with a microchannel containing an indicator solution whose position shift is captured by smartphone camera to infer IOP, with active US grants dated 2020, 2021, 2022, 2023, and 2025. A pending CA patent and a WO filing extend the family internationally.
CanadaSensimed SA
Sensimed SA holds approximately 4 retrieved filings across US (2014, 2016), EP (2014), and CA (2020) jurisdictions, anchored by the Triggerfish contact lens sensor — the only FDA-cleared device for continuous IOP-related pattern monitoring represented in this dataset. Patents describe a soft contact lens with an embedded pressure sensor that uses capillary-force shape adaptation against the cornea to sense IOP. The Triggerfish measures relative rather than absolute IOP, a documented limitation noted in retrieved literature.
SwitzerlandFive Innovation Signals in Smart IOP Monitoring (2024–2026)
Analysis of the most recent filings in this dataset (2024–2026) reveals five directional signals shifting the field from passive monitoring toward autonomous, multi-modal, and AI-driven ocular health platforms.
AI Integration and Predictive IOP Analytics
The 2025 filing from Meenakshi Academy of Higher Education and Research explicitly describes adaptive artificial intelligence algorithms for predictive ocular health assessment and IOP relief actuation — moving beyond passive monitoring to active prediction and intervention. The 2026 smart glass system from Chandigarh Group of Colleges (IN) integrates AI algorithms for real-time anomaly detection across multiple eye health metrics. These filings signal a convergence from data collection toward closed-loop autonomous management.
Closed-Loop Theranostic Sense-and-Treat Lenses
The POSTECH Academy-Industry Foundation wireless theranostic lens (US pending, 2023) integrates a strain sensor with a drug reservoir that releases therapeutic agents in real time based on IOP readings. A 2021 published paper described the first integrated wireless theranostic contact lens (WTCL) using an LCR cantilever circuit for ultra-sensitive IOP detection and electrically controlled drug delivery. These sense-and-treat architectures eliminate the delay between IOP detection and therapeutic response, representing a fundamental shift from monitoring toward autonomous ocular therapy.
MEMS Strain Gauge vs. Microfluidic Optical: Core Platform Comparison
Click any row to explore further.
| Dimension | MEMS Strain Gauge (Sensimed Triggerfish) | Microfluidic Optical (Kingston CLS) |
|---|---|---|
| Sensing Mechanism | Platinum or silicon strain gauge detects corneal curvature changes via capillary-force shape adaptation | Microchannel containing indicator solution; IOP-induced curvature change displaces fluid, read optically |
| Readout Method | Wireless RF telemetry to external antenna patch worn around the eye | Smartphone camera captures indicator fluid displacement; no dedicated hardware reader required |
| Electronics Required | Yes — embedded electronic circuit, wireless transmitter in lens | No — passive microfluidic system; all processing on smartphone |
| IOP Measurement Type | Relative IOP (pattern/trend); does not measure absolute IOP — documented limitation in retrieved literature | IOP-proportional indicator displacement; absolute calibration approach under development |
| Regulatory Status | FDA-cleared for 24-hour IOP-related pattern monitoring (Triggerfish CLS) — only cleared device in this dataset | Active US patents (2020–2025); pre-commercial stage as of dataset snapshot |
| Key Assignee | Sensimed SA (Switzerland) — ~4 retrieved filings across US, EP, CA | Kingston Health Sciences Centre (Canada) — ~7 retrieved filings across US, CA, WO |
| Sensitivity (Literature) | 289.5 μV/mmHg reported for platinum strain gauge CLS (2021 publication); temperature drift 33.4 μV/°C | IOP-proportional ring-couple interspace changes demonstrated in physiological range (2022 publication) |
| IP Priority Date | Foundational filings from 2001–2003 (Leuenberger/EPFL); Sensimed US/EP active from 2014 | 2016 priority date for all Kingston filings; continuously extended through 2025 |
Frequently Asked Questions: Smart Contact Lens IOP Monitoring Patents
Goldmann applanation tonometry — the clinical gold standard — delivers only a single-point IOP measurement during office hours. IOP follows a circadian rhythm with peaks frequently occurring between 11 PM and 5 AM. Most glaucoma patients have their highest IOP measurements outside clinic hours, and these undetected nocturnal peaks may explain why patients progress despite treatment.
Kingston Health Sciences Centre is the most prolific assignee in this dataset with approximately 7 retrieved filings across US, CA, and WO jurisdictions. All filings derive from a 2016 priority date and have been continuously extended through 2025, including active US grants dated 2020, 2021, 2022, 2023, and 2025.
The Sensimed Triggerfish is a contact lens sensor (CLS) that uses a soft lens with an embedded platinum or silicon strain gauge to detect corneal curvature changes associated with IOP fluctuations. It is the only FDA-cleared device for 24-hour IOP-related pattern monitoring represented in this dataset. A documented limitation is that it measures relative rather than absolute IOP.
A WTCL integrates IOP sensing with on-demand drug delivery in a single contact lens platform. When IOP exceeds a threshold, the system triggers release of a glaucoma medication via electrically controlled delivery. POSTECH Academy-Industry Foundation (South Korea) holds a pending US patent (2023) for this approach. A 2021 published paper described the first integrated WTCL using an LCR cantilever circuit for ultra-sensitive IOP detection and electrically controlled drug delivery.
Approximately 18 of the retrieved patent records originate from Indian jurisdictions, distributed across approximately 15 academic and engineering institutions. Nearly all are pending status, filed between 2021 and 2026. Most are at concept-patent stage with no commercial validation evidence, though they may represent partnership or licensing opportunities for larger medical device companies.
Microfluidic contact lens sensors embed microchannels in flexible contact lenses. Changes in IOP alter corneal curvature, changing channel volume and displacing an indicator fluid whose position is read optically — typically via a smartphone camera. This approach is passive (no embedded electronics required), aligns with low-cost monitoring goals, and is the basis of Kingston Health Sciences Centre’s patent family. The 2022 literature paper demonstrated IOP-proportional changes in ring-couple interspace using carbon dioxide laser-engraved commercial lenses.
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.